Dr. Kate Markey is a physician-scientist based in Seattle, Washington, whose work sits at a fascinating crossroads between the human gut, the immune system, and the outcomes of some of the most complex cancer treatments available today. She holds qualifications in medicine, immunology, and clinical research, and currently runs her own research group at the Fred Hutch Cancer Center, one of the most respected cancer research institutions in the world. She also sees patients directly, caring for people going through bone marrow transplants, which means her research isn’t just theoretical. It’s informed by real clinical experience with real patients facing serious illness.
| Details | Information |
|---|---|
| Full Name | Dr. Kate A. Markey |
| Known For | Physician-scientist specializing in transplant medicine, cancer research, and the relationship between the gut microbiome and cancer treatment outcomes |
| Gender | Female |
| Nationality | Australian |
| Birthplace | Australia |
| Education | MBBS and PhD from the University of Queensland, Brisbane, Australia; Master of Clinical Research from Monash University, Australia |
| Qualifications | MBBS, MClinRes, PhD, FRACP |
| Profession | Physician-Scientist, Oncologist, Assistant Professor, and Research Group Leader |
| Specialization | Hematology, Oncology, Bone Marrow Transplantation, and Gut Microbiome Research |
| Current Position | Assistant Professor, Division of Hematology and Oncology, University of Washington School of Medicine |
| Research Focus | The relationship between the gut microbiome, the immune system, and outcomes of immune-based cancer treatments, including bone marrow transplantation and cellular immunotherapies |
| Notable Research | Discovery of a link between the intestinal microbiome and chronic graft-versus-host disease (cGVHD) |
| Famous Works | Published research on microbiome and transplant outcomes, T-cell behavior after bone marrow transplantation, and graft-versus-host disease risk factors |
| Awards and Recognition | Recipient of the 2022 American Society of Hematology Research Scholar Award |
| Current Workplace | Fred Hutch Cancer Center, Seattle, Washington, and UW Medicine at the University of Washington Medical Center |
| Previous Workplaces | Memorial Sloan Kettering Cancer Center, New York; Princess Alexandra Hospital, Brisbane, Australia |
| Medical License | Licensed to practice medicine in Washington and New York |
| Areas of Focus | Bone marrow transplantation, graft-versus-host disease, gut microbiome research, cellular immunotherapies, and cancer treatment outcomes |
| Marital Status | Not publicly disclosed |
| Children | Not publicly disclosed |
| Residence | Seattle, Washington, United States |
| Career Start | Graduated from the University of Queensland in 2010 |
| Moved to USA | Relocated to the United States in 2018 to join Memorial Sloan Kettering Cancer Center in New York |
| Research Group | Leads an independent research laboratory at Fred Hutch Cancer Center, established in 2021 |
| Current Status | Actively practicing medicine and leading translational research programs at Fred Hutch Cancer Center |
| Legacy | Recognized as an emerging leader in microbiome and transplant medicine research, contributing to discoveries that may improve the prevention and treatment of bone marrow transplant complications |
What sets Dr. Markey apart from many researchers is that she operates on both sides of the equation. She spends time in the lab developing and testing ideas, and she also works directly with patients, which allows her to take what she observes clinically back into the research environment. This back and forth between bedside and bench is exactly how medical research should work, and it’s something she has spoken about as a core part of how she approaches her career. Her focus on the gut microbiome and its relationship to transplant outcomes and cancer therapy has positioned her as one of the more distinctive voices in this space.
Dr. Markey began her academic journey in Australia, where she completed a combined medical degree and PhD program at the University of Queensland in Brisbane, graduating in 2010. Before committing fully to medicine, she had actually started out studying engineering as an undergraduate, which gives her a slightly different analytical lens than most doctors carry. It was during that time that she got her first taste of laboratory research, helping set up a professor’s new lab, and she realized she loved how research could be applied directly to medicine and patient care. That early exposure changed her direction entirely.
After completing her medical degree and PhD, Dr. Markey continued building her skills through a Master of Clinical Research at Monash University in Australia, which she completed in 2018. That postgraduate qualification gave her new tools, particularly in areas like computational methods, advanced statistics, and working with large clinical datasets. She has described that period as a turning point, not just in terms of the skills she picked up, but in terms of how it shifted her research focus toward large scale clinical projects and the kind of data driven work she became known for afterward.
Dr. Markey holds qualifications as MBBS, MClin Res, PhD, and FRACP, reflecting a career that has spanned both clinical practice and research across two continents. She is currently an Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, as well as an Affiliate Investigator in the Clinical Research Division at Fred Hutch Cancer Center. She is licensed to practice medicine in both Washington and New York, and has affiliations with Fred Hutch Cancer Center and UW Medicine at the University of Washington Medical Center.
Dr. Markey’s interest in transplant medicine grew out of her early work in immunology, where she was looking at the biological mechanisms behind complications that arise after bone marrow transplants. As she moved through her training, she became increasingly drawn to the clinical side of transplantation, specifically caring for adult patients going through this process. Working directly with transplant patients gave her a front row seat to the challenges these treatments involve, and it pushed her research toward questions with direct real world relevance rather than purely theoretical ones.
At the heart of Dr. Markey’s research is a question that might seem surprising at first: what do the bacteria living in your gut have to do with how well cancer treatment works? It turns out, quite a lot. Her lab at Fred Hutch investigates the relationship between the gut microbiome, which refers to the trillions of microorganisms living in the intestines, and the outcomes of immune based cancer treatments including bone marrow transplantation and cellular immunotherapies. This is a relatively new area of cancer research, and Dr. Markey is one of the people helping define it.
One of the most significant areas of her work involves a condition called graft versus host disease, commonly known as GVHD. This is a serious complication that can occur after a bone marrow transplant, where immune cells donated by the transplant donor end up attacking the patient’s own healthy cells rather than just the cancer. Dr. Markey has specifically been looking at how the state of a patient’s gut microbiome before and after transplant influences whether GVHD develops and how severe it becomes. In 2026, her research produced findings showing a direct link between the intestinal microbiome and the development of chronic GVHD, a meaningful step forward in understanding and potentially preventing this complication.
The practical goal behind all of this research is straightforward: help more transplant patients get through treatment successfully with fewer serious complications. By understanding how the microbiome affects immune responses, Dr. Markey’s lab is working toward a point where doctors might be able to modify or protect a patient’s gut environment before transplant in order to reduce the risk of GVHD or improve how well the transplant controls the underlying cancer. Her lab works with both mouse models and clinical samples from real patients, which allows findings to move between the two settings and build toward treatments that are clinically applicable.
Dr. Markey’s career has involved significant personal commitment, including relocating from Australia to New York in 2018 to take up a position at Memorial Sloan Kettering Cancer Center, one of the most prestigious cancer hospitals in the world. That move gave her access to research opportunities and patient populations that simply weren’t available elsewhere. In 2021, she moved again, this time to Seattle to take up her current role at Fred Hutch and establish her own independent research group. Building a research lab from the ground up while maintaining a clinical practice takes a particular kind of dedication.
Dr. Markey has been open about what draws her to this kind of work. She has described loving the fact that research gives you access to the full picture, where clinical observations feed into lab questions, and lab findings loop back into patient care. Her engineering background probably plays into this too, bringing a systems thinking approach to problems that are inherently complex and involve multiple interacting components. The gut microbiome, the immune system, and cancer therapy are each complicated on their own. Looking at how they interact with each other requires a researcher who is comfortable with complexity.
Her work has earned recognition within the hematology and oncology community. In 2022, she was selected as a recipient of the American Society of Hematology Research Scholar Award, one of the most respected research awards in the field of blood disorders and hematology. This award specifically supports junior faculty who are transitioning from training into independent research careers, and being selected reflects the quality and promise of the work she was doing at that stage of her career.
Beyond the ASH Research Scholar Award, Dr. Markey has built an impressive publication record, contributing to research papers on topics ranging from the microbiome’s role in transplant outcomes to T cell behavior after bone marrow transplantation. Her work has appeared in major scientific journals and she has been invited to speak at precision medicine conferences, including the Precision Medicine World Conference, where she has presented her research findings to international audiences. She has also received funding from the American Cancer Society to continue her microbiome and GVHD research at Fred Hutch.
Dr. Markey is currently based in Seattle, Washington, where she leads her research group at Fred Hutch Cancer Center and sees patients through UW Medicine and the University of Washington Medical Center. Her lab continues to investigate the microbiome’s role in transplant outcomes and cancer therapy, with ongoing projects involving both pre-clinical mouse models and clinical patient samples. Her work is active and continuing, with recent findings published as recently as 2026 pointing to new connections between gut bacteria and chronic GVHD.
Who is Dr. Kate Markey?
She is a physician-scientist and oncologist based in Seattle, specializing in bone marrow transplantation and the relationship between the gut microbiome and cancer treatment outcomes.
Where does Dr. Kate Markey work?
She works at Fred Hutch Cancer Center and is an Assistant Professor at the University of Washington School of Medicine.
What is graft versus host disease and why does Dr. Markey study it?
GVHD is a complication of bone marrow transplants where donor immune cells attack the patient’s healthy tissue. Dr. Markey studies how the gut microbiome influences whether this condition develops and how serious it becomes.
What award did Dr. Markey receive in 2022?
She was selected as a recipient of the American Society of Hematology Research Scholar Award, one of the most prestigious honors in the field.
Where did Dr. Kate Markey train?
She completed her medical degree and PhD at the University of Queensland in Australia, followed by a Master of Clinical Research at Monash University, before moving to the United States to work at Memorial Sloan Kettering Cancer Center and later Fred Hutch.
Dr. Kate Markey represents the kind of researcher who makes a real difference not by chasing headlines but by working steadily on problems that matter enormously to real patients. Her focus on the gut microbiome and its connection to transplant outcomes is an area that didn’t exist in its current form even a decade ago, and she is one of the people helping build the evidence base that will shape how doctors approach these treatments in the future. Between her clinical work with transplant patients, her lab research, and her academic role at the University of Washington, she is contributing to medicine on multiple levels at once, and the field is better for it.
Will Lloyd is a British journalist, writer, and editor who has built a reputation as…
Sophia Wenzler is a British journalist, news presenter, and producer who has quietly but steadily…
Carlos Scola Pliego is a Spanish film director recognized for his contributions to the film…
Billie Henry is a name that often comes up when people search for information about…
Amy Corenswet is an American private figure who has come to public attention primarily through…
Mike Dobinson is a British business professional best known to the wider public as the…